SELLAS Life Sciences Group (SLS) Stock Looks Fully Valued After $154.6 Million Shelf Filing

Simply Wall St.06-17

AdvertisementWhy the new shelf registration matters for SELLAS Life Sciences Group stock SELLAS Life Sciences Group (SLS) has filed a $154.6 million shelf registration covering up to 20,000,000 common...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2644422157?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-06-17 22:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644422157","market":"nz","top_or_hot":-1,"title":"SELLAS Life Sciences Group (SLS) Stock Looks Fully Valued After $154.6 Million Shelf Filing","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy the new shelf registration matters for SELLAS Life Sciences Group stock SELLAS Life Sciences Group (SLS) has filed a $154.6 million shelf registration covering up to 20,000,000 common...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/sellas-life-sciences-group-sls-stock-looks-fully-valued-afte\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SELLAS Life Sciences Group (SLS) Stock Looks Fully Valued After $154.6 Million Shelf Filing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSELLAS Life Sciences Group (SLS) Stock Looks Fully Valued After $154.6 Million Shelf Filing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-17 22:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/sellas-life-sciences-group-sls-stock-looks-fully-valued-afte><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy the new shelf registration matters for SELLAS Life Sciences Group stock SELLAS Life Sciences Group (SLS) has filed a $154.6 million shelf registration covering up to 20,000,000 common...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/sellas-life-sciences-group-sls-stock-looks-fully-valued-afte\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/sellas-life-sciences-group-sls-stock-looks-fully-valued-afte","article_id":"2644422157","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/sellas-life-sciences-group-sls-stock-looks-fully-valued-afte","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2644422157","pubTimestamp":1781706686,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why the new shelf registration matters for SELLAS Life Sciences Group stock\nSELLAS Life Sciences Group (SLS) has filed a $154.6 million shelf registration covering up to 20,000,000 common shares, an event that puts potential future capital raising firmly on investors’ radar.\nThe filing follows recent shareholder meetings that backed board proposals and an expanded equity plan. This development sets the stage for possible use of this shelf as SELLAS funds its late stage oncology programs and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK7104":"黄金","SLS":"SELLAS Life Sciences Group Inc.","SLS.AU":"SOLSTICE MINERALS LTD"},"translate_title":"SELLAS Life Sciences Group(SLS)股票在提交1.546亿美元搁置申请后看起来已完全估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLS":1.5,"SLS.AU":1.5},"content_text":"AdvertisementWhy the new shelf registration matters for SELLAS Life Sciences Group stock SELLAS Life Sciences Group (SLS) has filed a $154.6 million shelf registration covering up to 20,000,000 common shares, an event that puts potential future capital raising firmly on investors’ radar. The filing follows recent shareholder meetings that backed board proposals and an expanded equity plan. This development sets the stage for possible use of this shelf as SELLAS funds its late stage oncology programs and ongoing operations. See our latest analysis for SELLAS Life Sciences Group. Against this backdrop, SELLAS Life Sciences Group’s share price has moved from intense weakness to strong momentum, with a 52.12% 90 day share price return and a very large 1 year total shareholder return of 382.69%, even though the 5 year total shareholder return remains down 36.40%. If this kind of move in SELLAS has your attention, it can be useful to compare it with other cancer and biotech stories by scanning 40 healthcare AI stocks With SELLAS Life Sciences Group stock up sharply over the past year and trading below the current analyst price target, the key question is whether the recent shelf news leaves room for more upside or if the market is already pricing in future growth. Preferred price to book multiple for SELLAS Life Sciences Group stock: Is it justified? For SELLAS Life Sciences Group, the key valuation reference point right now is its price to book ratio of about 13x, which stands out against peers and the wider US Biotechs industry. The price to book, or P/B, compares the company’s market value to its net assets on the balance sheet. For a late stage biotech like SELLAS, which currently reports no revenue and a net loss of $29.457m, a high P/B usually reflects strong expectations about future assets, such as the value investors ascribe to the pipeline and partnerships. Here, the market is paying a P/B of 13x for SELLAS Life Sciences Group, compared with around 2.4x for the US Biotechs industry and about 3.1x for its closest peers. That is a clear premium, which implies investors are pricing in much stronger prospects than the sector average, even though independent checks flag that SELLAS is currently unprofitable and has increased its losses over the past 5 years. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-book of 13x (OVERVALUED) However, SELLAS Life Sciences Group still carries key risks, including ongoing net losses of $29.457m and the potential dilution if the $154.6m shelf is fully used. Find out about the key risks to this SELLAS Life Sciences Group narrative. Next Steps With sentiment clearly mixed around SELLAS Life Sciences Group, it makes sense to move quickly and weigh both sides yourself using the 1 key reward and 3 important warning signs. Looking for more ideas beyond SELLAS Life Sciences Group? If SELLAS Life Sciences Group has sharpened your focus on opportunities, do not stop here. Broaden your watchlist with a few targeted stock ideas before the market moves.  Explore companies that appear mispriced today using the 44 high quality undervalued stocks. Scan for established dividend payers with the 9 dividend fortresses. Focus on businesses with stronger balance sheets using the 67 resilient stocks with low risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2644422157","isCrawlerRequest":true}